Drug Type Monoclonal antibody |
Synonyms DS 1103, DS 1103a, DS-1103a + [2] |
Target |
Action inhibitors |
Mechanism SIRPα inhibitors(Signal-regulatory protein alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | Phase 1 | United States | 11 Jan 2024 | |
| HER2 Positive Breast Cancer | Phase 1 | Japan | 11 Jan 2024 | |
| HER2 Positive Breast Cancer | Phase 1 | Belgium | 11 Jan 2024 | |
| HER2 Positive Breast Cancer | Phase 1 | Canada | 11 Jan 2024 | |
| HER2 Positive Breast Cancer | Phase 1 | France | 11 Jan 2024 | |
| HER2 Positive Breast Cancer | Phase 1 | Spain | 11 Jan 2024 | |
| Metastatic breast cancer | Phase 1 | United States | 11 Jan 2024 | |
| Metastatic breast cancer | Phase 1 | Japan | 11 Jan 2024 | |
| Metastatic breast cancer | Phase 1 | Belgium | 11 Jan 2024 | |
| Metastatic breast cancer | Phase 1 | Canada | 11 Jan 2024 |






